Stockholders awaiting action by the Food and Drug Administration on what they hope will be the next big thing couldn't be faulted for having some sleepless nights. But in Somaxon Pharmaceuticals' case, that would be most ironic.
Its new drug, Silenor, is a treatment for insomnia.
The Solana Beach-based firm is anxiously awaiting what they hope will be agency approval, possibly in early December. Standing by is Somaxon Vice President and General Counsel M... (continued)
Nov. 9, 2009
Matt Onaitis
Vice President and General Counsel of Somaxon Pharmaceuticals — Solana Beach
Read more about Matthew W. Onaitis...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Already a subscriber?
Sign In